top of page

Legend Biotech's CEO Ying Huang on moving CARVYKTI into earlier lines of treatment in the E.U. and U.S.

Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting for CARVYKTI, and highlight's Legend's R&D pipeline beyond BCMA.



コメント


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page